Data contact for ASIAN-HF study: Wee Qi Qi (NHCS) <wee.qi.qi@nhcs.com.sg> For site-specific data, site investigators can be individually contacted using details provided in the author block ([S1 Text](#pmed.1002916.s009){ref-type="supplementary-material"}).

Introduction {#sec008}
============

Obesity poses a major public health challenge globally, affecting 650 million worldwide, with a worrisome tripling of its prevalence over the last 20 years, especially among young adults in low- and middle-income countries \[[@pmed.1002916.ref001]\]. Ethnic differences in the association of body mass index (BMI) with clinical outcomes have been observed in the general population, with Asians being at higher risk of adverse events at lower BMI cutoffs compared to international standards \[[@pmed.1002916.ref002]\]. WHO has therefore recommended lower BMI cutoffs for the definition of obesity and clinical preventive efforts among Asians \[[@pmed.1002916.ref003]\].

Obesity is an antecedent risk factor of heart failure (HF). In established HF, however, a paradoxical relationship between obesity and outcomes has been described, where obese HF patients (defined by higher BMI) have better outcomes compared to those with lower BMI. This 'obesity paradox' was described mainly in Western cohorts of patients with HF with preserved ejection fraction (HFpEF) or HF with reduced ejection fraction (HFrEF) \[[@pmed.1002916.ref004]--[@pmed.1002916.ref006]\], and in limited Asian populations with HFrEF \[[@pmed.1002916.ref007],[@pmed.1002916.ref008]\]. Of note, we recently showed that Asians, particularly in Southeast Asia, are predisposed to a unique lean diabetic HFpEF phenotype \[[@pmed.1002916.ref009]\], with the worst outcomes among all HF phenotypes, including ischemic and non-ischemic HFrEF. Moreover, BMI is known to be a remarkably heterogeneous parameter and does not account for body fat distribution \[[@pmed.1002916.ref010]\]. Consideration of body fat distribution has gained momentum in recent years, with obesity measures other than BMI---including waist circumference, waist-to-hip ratio, waist-to-height ratio (WHtR), and body fat percentage---having better discriminatory capacity than BMI in predicting cardiovascular outcomes \[[@pmed.1002916.ref011],[@pmed.1002916.ref012]\]. Findings from TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) showed greater risk of mortality among HFpEF patients with higher waist circumference (≥102 cm in men, ≥88 cm in women) \[[@pmed.1002916.ref013]\]. Similarly, in BIOSTAT-CHF (BIOlogy Study to TAilored Treatment in Chronic Heart Failure), higher waist-to-hip ratio was linked to higher risk of death in women \[[@pmed.1002916.ref014]\]. There is a lack of data on waist circumference measurements in Asian patients with HF, and prior data using BMI are limited to HFrEF in Asia. Therefore, we sought to examine the association of obesity, defined by BMI versus waist circumference, with HF outcomes in patients with HFpEF and HFrEF in Asia.

Methods {#sec009}
=======

Study design, study population, and setting {#sec010}
-------------------------------------------

This study adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines ([S1 Checklist](#pmed.1002916.s001){ref-type="supplementary-material"}). Ethics approvals were obtained from the relevant human ethics committees at all sites ([S1 Table](#pmed.1002916.s002){ref-type="supplementary-material"}). The study complied with the Declaration of Helsinki, and all patients provided written informed consent.

We studied the association of obesity with outcomes using the Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry \[[@pmed.1002916.ref002],[@pmed.1002916.ref015]\]. The prospective study design, with details on sample size, of the ASIAN-HF registry has been published previously \[[@pmed.1002916.ref015]\]. Briefly, ASIAN-HF is a prospective observational multinational registry with patients with HF from 46 investigation sites in 11 Asian regions (Taiwan, Hong Kong, China, India, Malaysia, Thailand, Singapore, Indonesia, Philippines, Japan, and Korea) that enrolled patients between 1 October 2012 and 6 October 2016 ([S1 Text](#pmed.1002916.s009){ref-type="supplementary-material"}). The broad purpose of the ASIAN-HF registry was to determine the characteristics, mortality/morbidity, and risk factors for adverse outcomes among Asian patients with symptomatic HF (stage C). Although the specific primary analysis described in the study design \[[@pmed.1002916.ref015]\] related to investigating sudden cardiac death in HFrEF \[[@pmed.1002916.ref016]\], prespecified aims also included examining risk factors for outcomes (including both deaths and hospitalisations), as well as assessing the thresholds of traditional risk factors that are associated with increased risk in Asian patients.

The recruitment of patients with HFpEF was delayed by 1 year (9 September 2013 versus 1 October 2012) relative to the recruitment of patients with HFrEF, for funding reasons. For most of the recruitment period (until 6 October 2016), there was overlap in recruitment of both types of HF, and no apparent shifts in epidemiology were expected. Feasibility of follow-up throughout the duration of the study through periodic contact was ensured. The key inclusion criteria were \>18 years of age with symptomatic HF (at least 1 previous episode of decompensated HF in the previous 6 months resulting in a hospital admission or treatment in an outpatient clinic). Patients with severe valvular heart disease as a cause of HF, with a life-threatening comorbidity with a life expectancy \< 1 year, or who were unable or unwilling to give consent were excluded. All patients underwent physical examination at baseline: Waist circumference was measured in *n* = 2,051 patients, and BMI measurements were available for the entire cohort (*n* = 5,964).

Study definitions {#sec011}
-----------------

Patients were grouped by (1) BMI quartiles (\<21.8, 21.8 to \<24.5, 24.5 to \<27.8, and ≥27.8 kg/m^2^), (2) WHtR quartiles (\<0.51, 0.51 to \<0.55, 0.55 to \<0.60, and ≥0.60), and (3) 4 combined anthropometric groups of BMI (high, ≥24.5 kg/m^2^ \[obese\], or low, \<24.5 kg/m^2^ \[lean\]) and WHtR (high, ≥0.55 \[fat\], or low, \<0.55 \[thin\]) ([Fig 1](#pmed.1002916.g001){ref-type="fig"}).

![Central illustration of 4 combined groups of BMI (high, ≥24.5 kg/m^2^ \[obese\], or low, \<24.5 kg/m^2^ \[lean\]) and waist-to-height ratio (high, ≥0.55 \[fat\], or low, \<0.55 \[thin\]).\
QoL refers to the Kansas City Cardiomyopathy Questionnaire total symptom score. Key differences in characteristics between BMI/WHtR groups in bold. abv, above; BMI, body mass index; HFpEF, heart failure with preserved ejection fraction; NYHA, New York Heart Association; QoL, quality of life; WHtR, waist-to-height ratio.](pmed.1002916.g001){#pmed.1002916.g001}

The definitions of comorbidities in ASIAN-HF have been previously described \[[@pmed.1002916.ref002],[@pmed.1002916.ref015]\]. Coronary artery disease was defined as significant coronary obstruction on angiography, history of myocardial infarction, or prior revascularization. Hypertension was defined as the clinical diagnosis (blood pressure ≥ 140/90 mm Hg) and/or receiving anti-hypertensive medication. Diabetes was defined as prior history of diabetes and/or receiving anti-diabetic therapy. The Modification of Diet in Renal Disease (MDRD) Study equation was utilised to compute estimated glomerular filtration rate (eGFR), and chronic kidney disease was defined as eGFR \< 60 ml/min/1.73 m^2^. Health status was measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated 23-item patient-centred HF-specific questionnaire \[[@pmed.1002916.ref017]\]. Higher KCCQ domain scores (0 to 100) represent better health status.

Body composition analysis {#sec012}
-------------------------

In a group of HF patients recruited in Singapore (*n* = 311), bioelectrical impedance analysis was performed (InBody370; InBody, Cerritos, CA, US). Body weight, skeletal muscle mass, fat mass, and estimated trunk fat were measured using the direct segmental (right arm, left arm, trunk, right leg, left leg) method at 3 different frequencies (5 kHz, 50 kHz, and 250 kHz), as described previously \[[@pmed.1002916.ref018]\]. The variables trunk fat, skeletal muscle, and fat mass were calculated as percentage of body weight. In separate regression models, each of these body composition parameters was treated as the dependent variable, while waist-to-hip ratio was the independent variable, with the model adjusted for age, sex, and BMI.

Outcomes {#sec013}
--------

Patients were followed up for protocol-defined outcomes, which were adjudicated by an independent clinical endpoint committee. The primary outcome was the composite of 1-year all-cause mortality or hospitalisation for HF. Secondary outcomes were 1-year all-cause mortality, 1-year HF hospitalisation, 1-year cardiovascular mortality, and health-related quality of life (QoL) assessed with the KCCQ assessed at baseline. As a sensitivity analysis, the association of BMI and outcomes was also examined using WHO-recommended Asian cutoffs (\<18.5, 18.5 to \<23.0, 23.0 to \<27.5, and ≥27.5 kg/m^2^ for underweight, normal, overweight, and obese, respectively) in the whole cohort with follow-up data (*n* = 5,397). All data were prospectively documented in an electronic database capture, which was managed by a contract research organisation (IQVIA, formerly Quintiles) appointed by the academic executive committee.

Statistical analysis {#sec014}
--------------------

Baseline characteristics for the groups of patients were described using frequencies with percentages for categorical variables and means with standard deviations for continuous variables. Differences between groups were tested using Pearson χ² tests for categorical variables and ANOVA for continuous variables. A test of trend across the quartiles of WHtR and BMI was also performed. Restricted cubic regression splines were used to examine the association of BMI and WHtR with the composite outcome. Time-to-event analyses were examined using multivariable Cox proportional hazards models in the absence of violation of the proportional hazards assumption. Adjustments included age, sex, ethnicity, enrolment type (recruited during inpatient stay versus at outpatient clinic), New York Heart Association (NYHA) class, systolic blood pressure, heart rate, ejection fraction (EF), history of coronary artery disease, atrial fibrillation, diabetes, peripheral oedema, peripheral arterial vascular disease, and use of an angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB), beta blocker, diuretic, or mineralocorticoid receptor antagonist (MRA). The primary endpoint of 1-year all-cause mortality or HF hospitalisation was censored at 1 year or the last date of follow-up, whichever was earlier, in patients who did not have an event. To determine if HF subtype (i.e., HFrEF \[EF \< 40%\] or HFpEF \[EF ≥ 50%\]) modified the relationship between obesity and HF outcomes, the interaction between HF subtype and BMI/WHtR/combined anthropometric groups, adjusted for age, was examined in the Cox model. Sensitivity analysis of the relationship between BMI and HF outcomes was performed in the entire cohort. Marginal KCCQ domain scores, adjusted for age, sex, ethnicity, enrolment type, education, NYHA class, systolic blood pressure, heart rate, HF subtype, history of coronary artery disease, atrial fibrillation, and diabetes, were examined. In view of a reviewer's suggestion, sex-stratified analysis of the association of WHtR with HF outcomes was also performed.

Patients with incomplete data on adjusted clinical and demographic factors were excluded from multivariable logistic and Cox regression analyses. All analyses were performed with Stata/SE version 14.0 (StataCorp, College Station, TX, US).

Results {#sec015}
=======

Baseline characteristics {#sec016}
------------------------

In the entire cohort of 5,964 Asian patients with HF (mean age 61.3 ± 13.3 years, 26% women, 16% HFpEF), with increasing BMI category (WHO-recommended Asian cutoffs), patients were younger, with higher blood pressure, larger waist measures, greater prevalence of comorbidities (hypertension, diabetes and peripheral oedema), and higher QoL scores (*p*~trend~ \< 0.05; [S2 Table](#pmed.1002916.s003){ref-type="supplementary-material"}).

Asian patients with HF with (versus without) waist measures available were marginally younger (60.8 ± 12.9 versus 61.6 ± 13.5 years, *p =* 0.018), had a lower prevalence of HFpEF (6.8% versus 20.8%), belonged to less severe NYHA classes (68.5% versus 66.2%), had similar heart rate (78.8 ± 14.8 versus 78.8 ± 16.2 bpm), had similar BMI (25.0 ± 5.2 versus 25.4 ± 5.4 kg/m^2^), and had similar prevalence of both chronic kidney disease (43.7% versus 46.4%) and diabetes (40.4% versus 41.7%) ([S3 Table](#pmed.1002916.s004){ref-type="supplementary-material"}; *p \>* 0.05 for all).

Among 2,051 Asian patients with HF who had both BMI and WHtR measurements (mean age 60.8 ± 12.9 years, 24% women, 7% HFpEF), mean BMI and waist circumference were 25.0 ± 5.2 kg/m^2^ and 91.1 ± 12.5 cm; the 5th and 95th percentiles of BMI and WHtR were 18.3--34.2 kg/m^2^ and 0.45--0.70, respectively. Patients with HFpEF, compared to HFrEF, had higher mean BMI (27.1 ± 6.0 versus 24.2 ± 5.1 kg/m^2^) and waist circumference (98.2 ± 16.5 versus 90.7 ± 12.0 cm) (*p \<* 0.001 for both). Notably, half of patients with HFpEF (54.7%) had abdominal obesity (WHtR \> 0.60), in contrast to a quarter of HFrEF patients (23%) ([S4 Table](#pmed.1002916.s005){ref-type="supplementary-material"} and [Fig 2](#pmed.1002916.g002){ref-type="fig"}).

![Prevalence of HFpEF and HFrEF stratified by body mass index and waist-to-height ratio.\
HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.](pmed.1002916.g002){#pmed.1002916.g002}

Results with increasing BMI quartiles when restricted to patients with waist measures (*n =* 2,051; [S4 Table](#pmed.1002916.s005){ref-type="supplementary-material"}) were similar to those in the larger cohort (*n =* 5,964; [S2 Table](#pmed.1002916.s003){ref-type="supplementary-material"}), as described above. Larger WHtR (increasing WHtR quartiles) was associated with a higher proportion of women, higher BMI, and higher prevalence of hypertension, diabetes, and peripheral oedema (*p*~trend~ \< 0.001; [S4 Table](#pmed.1002916.s005){ref-type="supplementary-material"}). The highest WHtR quartile was associated with the lowest QoL overall summary score (63.3 ± 23.5), more so in HFpEF than HFrEF (*p*~interaction~ = 0.037).

In combined analyses of BMI and WHtR ([Table 1](#pmed.1002916.t001){ref-type="table"}), lean-fat (low BMI/high WHtR) patients (13.9%) had the highest proportion of women (35.4%), hypertension (55.1%), and diabetes (46.0%); were more likely to be from low-income countries or to be from South Asia or Southeast Asia; and had the lowest QoL scores (5--9 points lower than other groups), with respect to the self-efficacy (63.7 ± 29.1) and social limitation (59.9 ± 32.7) domains (*p \<* 0.05).

10.1371/journal.pmed.1002916.t001

###### Baseline characteristics and 1-year outcomes by BMI and WHtR groups.

![](pmed.1002916.t001){#pmed.1002916.t001g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                         Obese-thin\            Overall obese\          Overall lean\         Lean-fat\              *p*-Value (ANOVA/χ^2^)
                                                         (high BMI, low WHtR)   (high BMI, high WHtR)   (low BMI, low WHtR)   (low BMI, high WHtR)   
  ------------------------------------------------------ ---------------------- ----------------------- --------------------- ---------------------- ------------------------
  ***n***                                                283                    745                     738                   285                    

  **HFpEF**                                              15 (5.3%)              88 (11.8%)              21 (2.9%)             15 (5.3%)              **\<0.001**

  **Demographics**                                                                                                                                   

  Age, years                                             58.9 (12.7)            59.5 (12.6)             61.5 (13.4)           63.9 (11.9)            \<0.001

  Women                                                  39 (13.8%)             209 (28.1%)             144 (19.5%)           101 (35.4%)            \<0.001

  Ethnicity                                                                                                                                          0.011

   Chinese                                               57 (20.1%)             177 (23.8%)             175 (23.7%)           66 (23.2%)             

   Indian                                                113 (39.9%)            308 (41.3%)             279 (37.8%)           123 (43.2%)            

   Malay                                                 42 (14.8%)             86 (11.5%)              77 (10.4%)            38 (13.3%)             

   Japanese/Korean                                       23 (8.1%)              56 (7.5%)               93 (12.6%)            32 (11.2%)             

   Other (Thai, Filipino, indigenous)                    48 (17.0%)             118 (15.8%)             114 (15.4%)           26 (9.1%)              

  Geographical region, percent                                                                                                                       0.028

   Northeast Asia                                        56 (19.8%)             130 (17.4%)             180 (24.4%)           51 (17.9%)             

   South Asia                                            98 (34.6%)             279 (37.4%)             261 (35.4%)           114 (40.0%)            

   Southeast Asia                                        129 (45.6%)            336 (45.1%)             297 (40.2%)           120 (42.1%)            

  Country-level economic development                                                                                                                 \<0.001

   Low income                                            111 (39.2%)            316 (42.4%)             304 (41.2%)           136 (47.7%)            

   Middle income                                         118 (41.7%)            217 (29.1%)             236 (32.0%)           52 (18.2%)             

   High income                                           54 (19.1%)             212 (28.5%)             198 (26.8%)           97 (34.0%)             

  **Clinical characteristics**                                                                                                                       

  NYHA                                                                                                                                               0.740

   Class I or II                                         179 (69.6%)            483 (69.7%)             467 (67.1%)           187 (68.2%)            

   Class III or IV                                       78 (30.4%)             210 (30.3%)             229 (32.9%)           87 (31.8%)             

  Systolic blood pressure, mm Hg                         120.2 (18.6)           122.7 (20.2)            115.0 (18.9)          120.3 (19.3)           \<0.001

  Diastolic blood pressure, mm Hg                        73.5 (11.7)            74.1 (12.2)             71.2 (11.3)           71.4 (11.5)            \<0.001

  Heart rate, bpm                                        78.9 (15.9)            79.3 (14.8)             78.8 (15.0)           77.7 (13.0)            0.500

  BMI, kg/m^2^                                           26.6 (2.6)             29.6 (5.1)              21.0 (2.1)            22.1 (1.8)             \<0.001

  eGFR, ml/min/1.73 m^2^                                 64.4 (26.1)            65.8 (28.4)             65.9 (26.8)           64.1 (29.5)            0.770

  **Comorbidities**                                                                                                                                  

  Chronic kidney disease (eGFR \< 60 ml/min/1.73 m^2^)   85 (45.0%)             252 (44.4%)             231 (40.7%)           113 (47.7%)            0.280

  Ischemic HF                                            139 (49.1%)            351 (47.1%)             366 (49.7%)           144 (50.5%)            0.610

  Hypertension                                           151 (53.5%)            451 (60.6%)             322 (43.8%)           157 (55.1%)            \<0.001

  Coronary artery disease                                145 (51.4%)            380 (51.1%)             384 (52.2%)           152 (53.3%)            0.920

  Atrial fibrillation                                    31 (11.0%)             119 (16.0%)             118 (16.0%)           48 (16.8%)             0.170

  Myocardial infarction                                  91 (32.3%)             235 (31.6%)             234 (31.8%)           90 (31.6%)             0.997

  Diabetes                                               127 (45.0%)            339 (45.6%)             229 (31.1%)           131 (46.0%)            \<0.001

  Prior stroke                                           16 (5.7%)              55 (7.4%)               36 (4.9%)             25 (8.8%)              0.076

  Peripheral artery vascular disease                     6 (2.1%)               19 (2.6%)               22 (3.0%)             10 (3.5%)              0.740

  Peripheral oedema                                      55 (19.4%)             187 (25.1%)             125 (17.0%)           55 (19.3%)             0.001

  COPD                                                   16 (5.7%)              53 (7.1%)               54 (7.3%)             23 (8.1%)              0.720

  Smoking, ever                                          134 (47.5%)            318 (42.7%)             347 (47.2%)           109 (38.2%)            0.034

  Alcohol, ever                                          78 (27.7%)             215 (28.9%)             215 (29.3%)           67 (23.5%)             0.290

  **Medications**                                                                                                                                    

  ACEi or ARB                                            209 (74.9%)            543 (74.4%)             513 (70.8%)           188 (68.9%)            0.170

  Beta blocker                                           211 (75.6%)            569 (77.9%)             530 (73.1%)           194 (71.1%)            0.070

  Diuretic                                               207 (74.2%)            632 (86.6%)             599 (82.6%)           225 (82.4%)            \<0.001

  MRA                                                    149 (53.4%)            379 (51.9%)             406 (56.0%)           134 (49.1%)            0.200

  **Outcomes at 1 year**                                                                                                                             

  All-cause mortality                                    19 (8.1%)              62 (9.4%)               73 (11.7%)            36 (15.5%)             0.031

  Cardiovascular mortality                               18 (7.8%)              52 (8.1%)               63 (10.6%)            33 (14.5%)             0.026

  Composite outcome (all death + HF hospitalisation)     27 (11.5%)             103 (15.6%)             104 (16.7%)           51 (22.0%)             0.022

  **Quality of life at baseline (*n =* 1,990)**                                                                                                      

  Physical limitation score                              70.3 (25.2)            71.5 (24.4)             71.2 (25.6)           67.8 (27.5)            0.210

  Symptom stability score                                62.4 (26.7)            59.8 (27.3)             61.4 (27.7)           64.3 (28.1)            0.110

  Symptom frequency score                                72.3 (28.3)            70.0 (28.3)             71.5 (27.0)           69.1 (28.6)            0.430

  Symptom burden score                                   75.4 (27.4)            74.5 (26.2)             74.0 (25.6)           71.7 (27.7)            0.380

  Total symptom score                                    73.8 (27.0)            72.2 (26.2)             72.7 (25.5)           70.4 (27.4)            0.470

  Self-efficacy score                                    68.9 (26.4)            67.7 (27.3)             64.7 (27.4)           63.7 (29.1)            0.027

  Social limitation score                                68.8 (30.0)            65.4 (31.5)             63.2 (33.2)           59.9 (32.7)            0.011

  Overall summary score                                  67.7 (22.4)            66.4 (22.6)             65.6 (23.0)           63.3 (24.2)            0.130

  Clinical summary score                                 72.1 (23.3)            71.9 (22.5)             72.0 (22.8)           69.1 (24.9)            0.300
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data given as mean (standard deviation) or number (percent).

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; WHtR, waist-to-height ratio.

Overall obese (high BMI/high WHtR) patients (36.3%) were more likely to have HFpEF (11.8%), to be from South Asia/Southeast Asia, and to have hypertension (60.6%) and peripheral oedema (25.1%) (*p \<* 0.001 for all; [Table 1](#pmed.1002916.t001){ref-type="table"}).

Overall lean (low BMI/low WHtR) patients (36.0%) were more likely to have HFrEF (97.1%) and to be from Northeast Asia (24.4%), and had the lowest prevalence of comorbidities (hypertension, 43.8%; diabetes, 31.1%), compared to the other groups (*p \<* 0.001).

Obese-thin (high BMI/low WHtR) patients (13.8%) were younger, were more often men, and had the highest QoL scores, compared to the other groups. The obese-thin patients also had lower prevalence of hypertension (53.5% versus 60.6%), compared to the overall obese (*p \<* 0.05; [Table 1](#pmed.1002916.t001){ref-type="table"}).

Body composition analysis {#sec017}
-------------------------

Among the 311 patients with additional bioelectrical impedance data, baseline characteristics were similar to the overall cohort ([S5 Table](#pmed.1002916.s006){ref-type="supplementary-material"}). Patients who were overall obese (high BMI/high waist-to-hip ratio) had the highest percentage fat mass and trunk fat, followed by obese-thin (high BMI/low waist-to-hip ratio), lean-fat (low BMI/high waist-to-hip ratio), and overall lean (low BMI/low waist-to-hip ratio) (*p \<* 0.001; [S5 Table](#pmed.1002916.s006){ref-type="supplementary-material"}). Controlled for BMI, sex, and age, a 1-SD increase in waist-to-hip ratio was associated with a 0.38-unit increase in percent trunk fat (*p \<* 0.05).

Clinical outcomes and quality of life {#sec018}
-------------------------------------

Of the 2,051 Asian patients with both BMI and WHtR measurements available, follow-up data were complete in 1,746 (85.1%) patients, of whom 285 (16.3%) experienced the primary composite outcome of all-cause mortality or hospitalisation for HF within 1 year, and 190 (10.9%) patients died within 1 year.

Cubic spline regression models showed an inverse relationship between BMI and risk of the composite outcome; in contrast, there was a direct relationship between WHtR and risk of the composite outcome. The associations of BMI and WHtR with the composite outcome were not modified by HF subtype (i.e., HFpEF or HFrEF; *p*~interaction~ = 0.760 and 0.881 respectively; [Table 2](#pmed.1002916.t002){ref-type="table"}). Our sensitivity analysis showed similar results for BMI when the entire cohort with follow-up data was included (*n =* 5,397; [S6 Table](#pmed.1002916.s007){ref-type="supplementary-material"}) and when using WHO-recommended Asian BMI cutoffs ([Fig 3](#pmed.1002916.g003){ref-type="fig"}).

![Association of BMI and waist-to-height ratio with the composite outcome using cubic spline regression models and Cox proportional hazards models.\
Cubic spline regression models (A and C); Cox proportional hazards models (B and D). HR, hazard ratio.](pmed.1002916.g003){#pmed.1002916.g003}

10.1371/journal.pmed.1002916.t002

###### Association of BMI and WHtR with outcomes.

![](pmed.1002916.t002){#pmed.1002916.t002g}

  Outcome by BMI and WHtR                Number at risk   Number of events, *n* (%)   Unadjusted hazard ratio (95% CI)   *p*-Value                                     Adjusted[\*](#t002fn001){ref-type="table-fn"} hazard ratio (95% CI)   *p*-Value
  -------------------------------------- ---------------- --------------------------- ---------------------------------- --------------------------------------------- --------------------------------------------------------------------- ---------------------------------------------
  **1-year composite outcome**                                                                                                                                                                                                               
  BMI and WHtR                                                                                                           0.017[^†^](#t002fn002){ref-type="table-fn"}                                                                         0.058[^†^](#t002fn002){ref-type="table-fn"}
   Obese-thin (high BMI, low WHtR)       234              27 (11.5%)                  1.00 (Reference)                                                                 1.00 (Reference)                                                      
   Overall obese (high BMI, high WHtR)   658              103 (15.6%)                 1.40 (0.92, 2.14)                  0.121                                         1.52 (0.97, 2.40)                                                     0.068
   Overall lean (low BMI, low WHtR)      622              104 (16.7%)                 1.52 (1.00, 2.32)                  0.051                                         1.63 (1.03, 2.56)                                                     0.035
   Lean-fat (low BMI, high WHtR)         232              51 (22.0%)                  2.07 (1.30, 3.29)                  0.002                                         1.93 (1.17, 3.18)                                                     0.010
  **1-year all-cause mortality**                                                                                                                                                                                                             
  BMI and WHtR                                                                                                           0.025[^†^](#t002fn002){ref-type="table-fn"}                                                                         0.034[^†^](#t002fn002){ref-type="table-fn"}
   Obese-thin (high BMI, low WHtR)       234              19 (8.1%)                   1.00 (Reference)                                                                 1.00 (Reference)                                                      
   Overall obese (high BMI, high WHtR)   658              62 (9.4%)                   1.17 (0.70, 1.96)                  0.545                                         1.21 (0.70, 2.09)                                                     0.504
   Overall lean (low BMI, low WHtR)      622              73 (11.7%)                  1.49 (0.90, 2.47)                  0.121                                         1.67 (0.97, 2.87)                                                     0.065
   Lean-fat (low BMI, high WHtR)         232              36 (15.5%)                  2.04 (1.17, 3.55)                  0.012                                         2.01 (1.11, 3.65)                                                     0.022
  **1-year HF hospitalisation**                                                                                                                                                                                                              
  BMI and WHtR                                                                                                           0.103[^†^](#t002fn002){ref-type="table-fn"}                                                                         0.207[^†^](#t002fn002){ref-type="table-fn"}
   Obese-thin (high BMI, low WHtR)       234              10 (4.3%)                   1.00 (Reference)                                                                 1.00 (Reference)                                                      
   Overall obese (high BMI, high WHtR)   658              50 (7.6%)                   1.81 (0.92,3.57)                   0.088                                         1.84 (0.90, 3.79)                                                     0.096
   Overall lean (low BMI, low WHtR)      622              45 (7.2%)                   1.72 (0.87, 3.42)                  0.120                                         1.59 (0.78, 3.42)                                                     0.203
   Lean-fat (low BMI, high WHtR)         232              24 (10.3%)                  2.51 (1.20, 5.24)                  0.015                                         1.99 (0.91, 4.35)                                                     0.083

\*Adjusted for age, sex, ethnicity, enrolment type, New York Heart Association class, systolic blood pressure, heart rate, ejection fraction, history of coronary artery disease, atrial fibrillation, diabetes, peripheral oedema, peripheral artery vascular disease, and use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta blocker, diuretic, and mineralocorticoid receptor antagonist.

^†^Overall type III *p*-values for BMI/WHtR groups.

BMI, body mass index; WHtR, waist-to-height ratio.

Outcomes differed by BMI/WHtR groups. The risk of the composite outcome of death or HF hospitalisation was highest in the lean-fat (low BMI/high WHtR) group (51/232, 22.0%) and lowest in the obese-thin (high BMI/low WHtR) group (27/234, 11.5%). After adjustment for age, sex, HF subtype, NYHA class, systolic blood pressure, heart rate, comorbidities, and HF medications, the lean-fat (low BMI/high WHtR) group still had a higher risk of the composite outcome (adjusted hazard ratio 1.93, 95% CI 1.17--3.18, *p =* 0.010) ([Table 2](#pmed.1002916.t002){ref-type="table"}), compared to the obese-thin group. HF subtype (HFrEF or HFpEF) did not modify the association between the BMI/WHtR groups and the 1-year composite outcome (*p*~interaction~ = 0.355) ([Fig 4](#pmed.1002916.g004){ref-type="fig"}).

![Kaplan--Meier survival curves of the composite outcome for combined BMI/WHtR groups.\
BMI, body mass index; WHtR, waist-to-height ratio.](pmed.1002916.g004){#pmed.1002916.g004}

Similar patterns were observed with 1-year all-cause mortality and HF hospitalisation. The mortality event rate (36/232, 15.5%) and adjusted risk of all-cause mortality were higher in the lean-fat (low BMI/high WHtR) group (adjusted hazard ratio 2.01, 95% CI 1.11--3.65, *p =* 0.022) than in the obese-thin group ([Table 2](#pmed.1002916.t002){ref-type="table"}). Results were similar in both HF subtypes (*p*~interaction~ = 0.609). Cardiovascular mortality was also higher in the lean-fat group (33/232, 14.5%) than in the obese-thin group (*p =* 0.026; [Table 1](#pmed.1002916.t001){ref-type="table"}). In sex-stratified analysis, higher WHtR (≥0.60) was associated with higher risk of death in both men and women, as observed in the overall cohort. However, our current study is underpowered to have such sex-specific conclusions statistically confirmed, as evident from the low number of events and large confidence intervals, especially in women ([S7 Table](#pmed.1002916.s008){ref-type="supplementary-material"}).

With regards to QoL, the adjusted mean overall scores were not different between the 4 groups (*p =* 0.544). The lean-fat (low BMI/high WHtR) patients had lower adjusted mean social limitation scores compared to the obese-thin (high BMI/low WHtR) patients (61.9 versus 67.5, *p =* 0.034), while the difference in self-efficacy scores was attenuated after adjustment for demographic and clinical confounders (*p =* 0.510) ([Table 3](#pmed.1002916.t003){ref-type="table"}).

10.1371/journal.pmed.1002916.t003

###### Adjusted mean Kansas City Cardiomyopathy Questionnaire domain scores, by BMI/WHtR group.

![](pmed.1002916.t003){#pmed.1002916.t003g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Quality of life domains     Obese-thin\            Overall obese\          Overall lean\                                     Lean-fat\                                         *p*-Value
                              (high BMI, low WHtR)   (high BMI, high WHtR)   (low BMI, low WHtR)                               (low BMI, high WHtR)                              
  --------------------------- ---------------------- ----------------------- ------------------------------------------------- ------------------------------------------------- -----------
  *n*                         264                    726                     718                                               282                                               

  Physical limitation score   69.0 (1.4)             71.0 (0.9)              71.2 (0.9)                                        69.3 (1.4)                                        0.396

  Symptom stability score     62.8 (1.8)             60.7 (1.1)              61.5 (1.1)                                        64.6 (1.7)                                        0.241

  Symptom frequency score     71.1 (1.5)             69.9 (0.9)              70.9 (0.9)                                        70.0 (1.4)                                        0.836

  Symptom burden score        74.1 (1.5)             74.3 (0.9)              73.5 (0.9)                                        72.7 (1.4)                                        0.780

  Total symptom score         72.6 (1.4)             72.1 (0.9)              72.2 (0.9)                                        71.4 (1.4)                                        0.934

  Self-efficacy score         67.5 (1.6)             66.8 (1.0)              65.3 (1.0)                                        65.0 (1.5)                                        0.510

  Social limitation score     67.5 (1.9)             65.1 (1.2)              63.1 (1.1)[\*](#t003fn002){ref-type="table-fn"}   61.9 (1.9)[\*](#t003fn002){ref-type="table-fn"}   0.102

  Overall summary score       66.6 (1.2)             66.1 (0.8)              65.4 (0.7)                                        64.4 (1.2)                                        0.544

  Clinical summary score      70.7 (1.2)             71.6 (0.7)              71.7 (0.7)                                        70.3 (1.2)                                        0.711
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data presented are adjusted mean scores (standard error of mean) (adjusted for age, sex, ethnicity, enrolment type, education, New York Heart Association class, systolic blood pressure, heart rate, heart failure subtype, history of coronary artery disease, atrial fibrillation, and diabetes).

\**p \<* 0.05 compared against the obese-thin group.

BMI, body mass index; WHtR, waist-to-height ratio.

Discussion {#sec019}
==========

To our knowledge, this study provides the first prospective multinational data on the association of BMI versus WHtR with outcomes among Asian patients with HFpEF and HFrEF. We found a number of interesting results. First, BMI and abdominal obesity have directionally opposite relationships with outcomes---lower BMI, but higher WHtR, was associated with worse outcomes. Second, patients who were lean-fat (low BMI/high WHtR) were more likely to be women, to be from low-income countries or South/Southeast Asia, and to have the highest burden of diabetes, poorest QoL, and worst composite outcome. Third, results were consistent regardless of type of HF (HFpEF or HFrEF).

Previous reports on obesity and clinical outcomes in HF have predominantly relied on a single anthropometric measure of obesity (BMI or waist circumference or waist-to-hip ratio or WHtR) or examined these measurements in isolation from one another. Studies solely using BMI have consistently reported an obesity paradox, with overweight and obese patients with HF having better prognosis than their lean counterparts in both HFpEF and HFrEF \[[@pmed.1002916.ref004]--[@pmed.1002916.ref006],[@pmed.1002916.ref011]\]. However, more recent reports using measures of abdominal obesity have challenged this concept. Unlike for BMI, higher waist circumference was associated with higher risk of mortality across a wide range of left ventricular EF values \[[@pmed.1002916.ref014]\], particularly HFpEF \[[@pmed.1002916.ref013]\]. A combined measure of BMI and waist circumference showed higher risk of mortality in overall obese patients with high BMI and high waist circumference \[[@pmed.1002916.ref019]\]. However, this was a single-centre study (*n =* 344) that included only patients with HFrEF. Our findings extend the prior literature by showing the association of combined measures of BMI/WHtR and outcomes in a large, well-characterised multinational Asian cohort of patients with HFrEF and HFpEF.

Our most striking finding is that BMI and WHtR have directionally contrasting relationships with clinical outcomes---higher BMI is associated with better, and higher WHtR with worse, outcomes. Despite lower BMI on average in Asian patients with HF compared to Western cohorts, we confirmed that the obesity paradox still applies to the Asian HF population when BMI is used to index obesity. This is consistent with limited previous reports from East Asia \[[@pmed.1002916.ref007],[@pmed.1002916.ref008]\], but our data are the first to our knowledge available from wider geography including Southeast and South Asia. Higher metabolic reserve in face of the catabolic effects of HF is suggested as an explanation for the BMI paradox \[[@pmed.1002916.ref010]\]. Although BMI is a convenient measure, it is known that it fails to distinguish between (1) components of body composition (fat mass, lean mass, skeletal muscle mass), (2) different body fat distributions (central versus peripheral adipose depots), and (3) fluid accumulation in decompensated HF and absolute weight gain \[[@pmed.1002916.ref010]\].

In contrast to the findings for BMI, we observed that higher WHtR was associated with higher 1-year mortality and composite outcome, similar to some previous studies \[[@pmed.1002916.ref013],[@pmed.1002916.ref014]\] but not others \[[@pmed.1002916.ref019]\]. Consistent with our findings, higher waist circumference was associated with higher risk of all-cause mortality in the pure HFpEF cohort of TOPCAT, despite a strong paradoxical relationship between BMI and outcomes \[[@pmed.1002916.ref013]\]. In the European BIOSTAT-CHF HF population \[[@pmed.1002916.ref014]\], an association between higher waist-to-hip ratio and higher mortality was observed only in women, whereas we found similar associations in men and women in ASIAN-HF (i.e., sex did not modify the relationship between WHtR and outcomes in our study; *p*~interaction~ \> 0.5). One other single-centre study, including only patients with HFrEF (*n =* 344) \[[@pmed.1002916.ref019]\], reported contrary results in that HFrEF patients with normal BMI/normal waist circumference had the highest hazards of 2-year mortality compared to those with high BMI/high waist circumference---discordant results that may be due to exclusion of lean patients (with BMI \< 18.5 kg/m^2^) and patients with HFpEF, in whom prevalence of central obesity is higher. Importantly, our study is the first demonstration to our knowledge of the impact of WHtR, an index of central obesity, on HF outcomes in Asia. While there was greater prevalence of central obesity among patients with HFpEF than HFrEF, it was equally associated with worse outcomes in both HF subtypes. Indeed, abdominal measures of adiposity (waist circumference, waist-to-hip ratio, WHtR) more accurately reflect body composition than BMI \[[@pmed.1002916.ref020]\]. Mechanistic insights into abdominal adiposopathy include suggestions of a pro-inflammatory pathology. Adipose tissues actively produce inflammatory cytokines, potentially leading to diastolic dysfunction \[[@pmed.1002916.ref021]\]. Experimental models have shown strong relationships between visceral obesity and increased cardiac macrophage infiltration and cytokine gene expression, exacerbating myocardial hypertrophy, fibrosis, and injury \[[@pmed.1002916.ref022]\].

Our findings highlight a particularly susceptible group of lean-fat (low BMI/high WHtR) patients who were more likely to be women, with a higher prevalence of diabetes, poorer QoL scores, and worse composite outcome, compared to all other groups. Central adiposity is associated with cardiac dysfunction, independent of BMI, even in lean individuals \[[@pmed.1002916.ref023]\]. The thrifty gene hypothesis, maternal insufficiency, foetal undernutrition, and differences in body fat distribution have been suggested to contribute to the higher prevalence of lean diabetes in Asia \[[@pmed.1002916.ref024],[@pmed.1002916.ref025]\]. Our preliminary evidence from body composition analysis showing that higher waist-to-hip ratio was independently linked with higher trunk fat and lower skeletal muscle mass suggests the presence of sarcopenia in the lean-fat patients. Whether sarcopenia may be a treatable target in HF remains to be proven. Interestingly, the commonly observed BMI paradox is obliterated when cardiorespiratory fitness is increased/preserved \[[@pmed.1002916.ref026]\], presumably due to preservation of skeletal muscle mass. It is also noteworthy that most of the lean-fat patients in our study were from South Asia and Southeast Asia, while patients from Northeast Asia were more likely to be overall lean. Indeed, ethnic differences in body fat distribution have been reported previously in the INSPIRE ME IAA study, which included white, black, Hispanic, East Asian, and South Asian individuals. CT-scan assessment revealed that East Asians, followed by South Asians, had a more detrimental abdominal fat deposition, despite low BMI \[[@pmed.1002916.ref027]\].

Asians exhibit remarkable variability in body fat distribution for a given BMI, and viscerally obese patients with HF have the worst outcomes. Information from a single anthropometric measure in isolation fails to provide the necessary insights into body fat distribution. More accurate estimators of visceral fat, such as computer tomography scans, magnetic resonance imaging, and dual energy X-ray absorptiometry, are cost intensive or involve the risk of radiation \[[@pmed.1002916.ref010]\]. Whilst not perfect, a combination measure of BMI and WHtR is a simple and convenient alternative for estimation of body fat distribution. Targeting visceral obesity with inhibitors of aldosterone, neprilysin, and, particularly, sodium glucose transporter 2 (SGLT2) have been suggested for management of obesity-related HF, pending confirmation from ongoing large-scale trials \[[@pmed.1002916.ref028]\].

Strengths and limitations {#sec020}
-------------------------

Selection bias and residual confounding are inevitable in such multinational observational studies. Lack of repeat assessments of BMI or waist measures precludes any inferences involving loss of muscle mass in the progression of HF. Unmeasured factors such as differences in healthcare system, economic development, and nutritional status across the regions are potential confounders. Patients with body composition analysis are more recent recruits who do not have follow-up data available for outcome analysis. Key strengths of this study include the prospective design, that the study spans across widespread geography in Asia (46 centres from 11 regions), uniform data collection, meticulous follow-up, and independent adjudication of outcomes. We utilised abdominal measures and body composition data in addition to BMI to investigate the obesity paradox in both HFpEF and HFrEF in Asia.

Implications and next steps {#sec021}
---------------------------

Obesity in HF poses formidable public health challenges for health policymakers, health service providers, and patient caregivers in many low- and middle-income countries. The controversy surrounding the obesity paradox makes it even more challenging for clinicians to manage concomitant HF and obesity. Combined usage of BMI and abdominal measures could potentially inform HF management better, especially among the particularly vulnerable patients with low BMI and high WHtR. Clear national policies that underscore prevention of abdominal obesity and promotion of a healthy BMI, through awareness, education, and lifestyle modification, need to be championed.

Conclusion {#sec022}
==========

Among Asian patients with HF, we observed that higher BMI was associated with better outcomes whereas higher WHtR conferred worse outcomes. Our findings highlight a particularly susceptible group of lean-fat (low BMI/high WHtR) patients who were more likely to be women, with a higher prevalence of diabetes, poorer QoL scores, and worse composite outcome, compared to all other groups.
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WHtR

:   waist-to-height ratio

[^1]: I have read the journal\'s policy and the authors of this manuscript have the following competing interests: CSPL served as a guest editor on *PLOS Medicine*\'s Cardiovascular Disease Special Issue. Unrelated to present work, CSPL is supported by a Clinician Scientist Award from the National Medical Research Council Singapore, non-financial support from Boston Scientific, non-financial support from Bayer, non-financial support from Thermofisher, non-financial support from Vifor Pharma, other from Bayer, other from Novartis, other from Takeda, other from Merck, other from Astra Zeneca, other from Janssen Research & Development, other from LLC, other from Menarini, other from Boehringer Ingelheim, other from Abbott Diagnostics, from DC Devices, outside the submitted work; In addition, CSPL has a patent PCT/SG2016/050217 pending. AMR is supported by a Singapore Translational Research (STaR) award from the National Medical Research Council Singapore, is a named investigator on projects supported by grants from Boston Scientific, Bayer, Astra Zeneca, Roche Diagnostics and has received research support in kind Thermo Fisher, Roche Diagnostics and Abbott Laboratories and other from Novartis. All other authors report no conflict of interest, financial or otherwise.

[^2]: ¶ Membership of ASIAN-HF Investigators is provided in [S1 Text](#pmed.1002916.s009){ref-type="supplementary-material"}.
